Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine
スポンサーリンク
概要
- 論文の詳細を見る
- 2011-12-01
著者
-
Slosar Paul
Spinecare Medical Group San Francisco Spine Institute
-
BURKUS J.
The Hughston Clinic
-
Glassman Steven
Spine Institute
-
Rosner Michael
Walter Reed Army Medical Center
-
GORNET Matthew
The Orthopedic Center of St. Louis
-
DECKEY Jeffrey
Orthopaedic Specialty Institute Medical Group of Orange County
-
NOWAK John
Pfizer Inc, Pharmacokinetics, Dynamics, and Metabolism
-
HATCHER Brian
Medtronic Spinal and Biologics
-
Nowak John
Pfizer Inc Pharmacokinetics Dynamics And Metabolism
-
SLOSAR Paul
SpineCare Medical Group
関連論文
- A Clinical Impact Classification of Scoliosis in the Adult
- The Validity of the SRS-22 Instrument in an Adult Spinal Deformity Population Compared With the Oswestry and SF-12 : A Study of Response Distribution, Concurrent Validity, Internal Consistency, and Reliability
- Patient Satisfaction After Circumferential Lumbar Fusion
- Does Treatment (Nonoperative and Operative) Improve the Two-Year Quality of Life in Patients With Adult Symptomatic Lumbar Scoliosis : A Prospective Multicenter Evidence-Based Medicine Study
- Short-term Osteoclastic Activity Induced by Locally High Concentrations of Recombinant Human Bone Morphogenetic Protein-2 in a Cancellous Bone Environment
- Operative Versus Nonoperative Treatment of Leg Pain in Adults With Scoliosis : A Retrospective Review of a Prospective Multicenter Database With Two-Year Follow-up
- Changes in Radiographic and Clinical Outcomes With Primary Treatment Adult Spinal Deformity Surgeries From Two Years to Three- to Five-Years Follow-up
- Letters
- Indications and Outcomes of Reconstructive Surgery in Chronic Pain of Spinal Origin
- Letters
- The Scoliosis Research Society Health-Related Quality Of Life (SRS-30) Age-Gender Normative Data : An Analysis of 1346 Adult Subjects Unaffected by Scoliosis
- Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine